CPRiL

4 Functional Relationships(s) Download
	Sentence	Compound Name	Protein Name	Organism
1	Sorafenib-induced phosphorylation of c-met, p70S6K and 4EBP1 was significantly reduced when 10-0505 cells were co-treated with anti-human anti-HGF antibody, suggesting that treatment with sorafenib leads to increased HGF secretion and activation of c-met and mTOR targets.	Sorafenib	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens
2	Sorafenib-induced phosphorylation of c-met, p70S6K and 4EBP1 was significantly reduced when 10-0505 cells were co-treated with anti-human anti-HGF antibody, suggesting that treatment with sorafenib leads to increased HGF secretion and activation of c-met and mTOR targets.	Sorafenib	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens
3	Sorafenib-induced phosphorylation of c-met, p70S6K and 4EBP1 was significantly reduced when 10-0505 cells were co-treated with anti-human anti-HGF antibody, suggesting that treatment with sorafenib leads to increased HGF secretion and activation of c-met and mTOR targets.	Sorafenib	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens
4	Sorafenib-induced phosphorylation of c-met, p70S6K and 4EBP1 was significantly reduced when 10-0505 cells were co-treated with anti-human anti-HGF antibody, suggesting that treatment with sorafenib leads to increased HGF secretion and activation of c-met and mTOR targets.	Sorafenib	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens